These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 27761835)
1. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors. Lopez G; Pollock RE Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835 [TBL] [Abstract][Full Text] [Related]
2. HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). Lopez G; Bill KL; Bid HK; Braggio D; Constantino D; Prudner B; Zewdu A; Batte K; Lev D; Pollock RE PLoS One; 2015; 10(7):e0133302. PubMed ID: 26200462 [TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Rettig I; Koeneke E; Trippel F; Mueller WC; Burhenne J; Kopp-Schneider A; Fabian J; Schober A; Fernekorn U; von Deimling A; Deubzer HE; Milde T; Witt O; Oehme I Cell Death Dis; 2015 Feb; 6(2):e1657. PubMed ID: 25695609 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma. Umamaheswari A; Puratchikody A; Hari N Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926 [TBL] [Abstract][Full Text] [Related]
5. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. Lee MJ; Tsai YJ; Lin MY; You HL; Kalyanam N; Ho CT; Pan MH Phytomedicine; 2019 Apr; 57():377-384. PubMed ID: 30831486 [TBL] [Abstract][Full Text] [Related]
6. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197 [TBL] [Abstract][Full Text] [Related]
7. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873 [TBL] [Abstract][Full Text] [Related]
8. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Yan W; Liu S; Xu E; Zhang J; Zhang Y; Chen X; Chen X Oncogene; 2013 Jan; 32(5):599-609. PubMed ID: 22391568 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity. Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254 [TBL] [Abstract][Full Text] [Related]
11. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy. Lopez G; Torres K; Lev D Autophagy; 2011 Apr; 7(4):440-1. PubMed ID: 21224727 [TBL] [Abstract][Full Text] [Related]
12. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831 [TBL] [Abstract][Full Text] [Related]
13. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595 [TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Watters JM; Wright G; Smith MA; Shah B; Wright KL Biochem Biophys Res Commun; 2021 Jan; 534():773-779. PubMed ID: 33190829 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810 [TBL] [Abstract][Full Text] [Related]
17. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255 [TBL] [Abstract][Full Text] [Related]
18. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202 [TBL] [Abstract][Full Text] [Related]
19. Discovery of the first histone deacetylase 6/8 dual inhibitors. Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185 [TBL] [Abstract][Full Text] [Related]
20. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]